Barbara Geeroms1,2, Wim Laleman3, Annouschka Laenen4,5, Sam Heye1,2, Chris Verslype3, Schalk van der Merwe3, Frederik Nevens3, Geert Maleux6,7. 1. Department of Radiology, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium. 2. Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. 3. Department of Hepatology, University Hospitals Leuven, Leuven, Belgium. 4. Interuniversity Institute for Biostatistics and Statistical Bioinformatics, KU Leuven, Leuven, Belgium. 5. University of Hasselt, Hasselt, Belgium. 6. Department of Radiology, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium. geert.maleux@uzleuven.be. 7. Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. geert.maleux@uzleuven.be.
Abstract
PURPOSE: To retrospectively analyse long-term patency and overall survival of cirrhotic patients treated with TIPSS using e-PTFE-covered stents. Additionally, prognostic factors for better patency and survival were analysed. MATERIALS AND METHODS: Two hundred and eighty-five consecutive cirrhotic patients with severe portal hypertension-related symptoms were included. Follow-up, including clinical assessment and duplex ultrasound, was analysed up to end of study, patient's death, liver transplantation or TIPSS-reduction. Patency rates and overall survival were estimated by the Kaplan-Meier method; potential differences in outcome between subgroups were calculated using the Pepe and Mori test. RESULTS: The 1-, 2- and 5-year primary patencies were 91.5 %, 89.2 % and 86.2 %, respectively, with no new shunt dysfunctions after 5 years' follow-up. TIPSS revision was performed more often in ascites patients (P = 0.02). The 1-, 4- and 10-year survival rates were 69.2 %, 52.1 % and 30.7 %, respectively. Survival was higher in Child-Pugh class A-B (P = 0.04), in the recurrent bleeding group (P = 0.008) and in patients with underlying alcoholic cirrhosis (P = 0.01). CONCLUSION: Long term, primary patency of e-PTFE-covered TIPSS stents remains very high (>80 %); shunt revision was required more frequently in ascites patients. Overall survival was better in Child-Pugh A-B patients with recurrent variceal bleeding and alcoholic liver cirrhosis. KEYPOINTS: • Long-term primary patency rate of e-PTFE-covered TIPSS stents remains very high. • No new shunt dysfunction was found after 5 years of follow-up. • Shunt revision was required more frequently in ascites patients. • Four and 10 years' overall survival was 50 and 30 %, respectively.
PURPOSE: To retrospectively analyse long-term patency and overall survival of cirrhotic patients treated with TIPSS using e-PTFE-covered stents. Additionally, prognostic factors for better patency and survival were analysed. MATERIALS AND METHODS: Two hundred and eighty-five consecutive cirrhotic patients with severe portal hypertension-related symptoms were included. Follow-up, including clinical assessment and duplex ultrasound, was analysed up to end of study, patient's death, liver transplantation or TIPSS-reduction. Patency rates and overall survival were estimated by the Kaplan-Meier method; potential differences in outcome between subgroups were calculated using the Pepe and Mori test. RESULTS: The 1-, 2- and 5-year primary patencies were 91.5 %, 89.2 % and 86.2 %, respectively, with no new shunt dysfunctions after 5 years' follow-up. TIPSS revision was performed more often in ascites patients (P = 0.02). The 1-, 4- and 10-year survival rates were 69.2 %, 52.1 % and 30.7 %, respectively. Survival was higher in Child-Pugh class A-B (P = 0.04), in the recurrent bleeding group (P = 0.008) and in patients with underlying alcoholic cirrhosis (P = 0.01). CONCLUSION: Long term, primary patency of e-PTFE-covered TIPSS stents remains very high (>80 %); shunt revision was required more frequently in ascites patients. Overall survival was better in Child-Pugh A-B patients with recurrent variceal bleeding and alcoholic liver cirrhosis. KEYPOINTS: • Long-term primary patency rate of e-PTFE-covered TIPSS stents remains very high. • No new shunt dysfunction was found after 5 years of follow-up. • Shunt revision was required more frequently in ascites patients. • Four and 10 years' overall survival was 50 and 30 %, respectively.
Authors: Zhen W Zhuang; Gao J Teng; Robert F Jeffery; John M Gemery; B Janne d'Othee; Michael A Bettmann Journal: AJR Am J Roentgenol Date: 2002-12 Impact factor: 3.959
Authors: G Maleux; N A Perez-Gutierrez; S Evrard; A Mroue; O Le Moine; W Laleman; F Nevens Journal: Acta Gastroenterol Belg Date: 2010 Jul-Sep Impact factor: 1.316
Authors: Zachary L Bercu; Aaron M Fischman; Edward Kim; F Scott Nowakowski; Rahul S Patel; Thomas D Schiano; Charissa Y Chang; Robert A Lookstein Journal: AJR Am J Roentgenol Date: 2015-03 Impact factor: 3.959
Authors: Dhiraj Tripathi; Ahmed Helmy; Kim Macbeth; Sherzad Balata; Hock F Lui; Adrian J Stanley; Doris N Redhead; Peter C Hayes Journal: Eur J Gastroenterol Hepatol Date: 2004-01 Impact factor: 2.566
Authors: Christophe Bureau; Juan Carlos Garcia Pagan; Gilles Pomier Layrargues; Sophie Metivier; Pablo Bellot; Pierre Perreault; Philippe Otal; Juan-G Abraldes; Jean Marie Peron; Hervé Rousseau; Jaume Bosch; Jean Pierre Vinel Journal: Liver Int Date: 2007-08 Impact factor: 5.828
Authors: Klaus A Hausegger; Franz Karnel; Buriana Georgieva; Josef Tauss; Horst Portugaller; Hannes Deutschmann; Andrea Berghold Journal: J Vasc Interv Radiol Date: 2004-03 Impact factor: 3.464
Authors: Pieter C J ter Borg; Mirjam Hollemans; Henk R Van Buuren; Frank P Vleggaar; Michael Groeneweg; Wim C J Hop; Johan S Laméris Journal: Radiology Date: 2004-03-24 Impact factor: 11.105
Authors: Rosalie C Oey; Koos de Wit; Adriaan Moelker; Tugce Atalik; Otto M van Delden; Geert Maleux; Nicole S Erler; R Bart Takkenberg; Robert A de Man; Frederik Nevens; Henk R van Buuren Journal: Aliment Pharmacol Ther Date: 2018-08-22 Impact factor: 8.171
Authors: Guruprasad P Aithal; Naaventhan Palaniyappan; Louise China; Suvi Härmälä; Lucia Macken; Jennifer M Ryan; Emilie A Wilkes; Kevin Moore; Joanna A Leithead; Peter C Hayes; Alastair J O'Brien; Sumita Verma Journal: Gut Date: 2020-10-16 Impact factor: 23.059
Authors: Michael Bernhard Pitton; Arndt Weinmann; Roman Kloeckner; Jens Mittler; Christian Ruckes; Christoph Düber; Gerd Otto Journal: Cardiovasc Intervent Radiol Date: 2021-12-01 Impact factor: 2.740
Authors: Carsten Meyer; Alba Maria Paar Pérez; Johannes Chang; Alois Martin Sprinkart; Nina Böhling; Andreas Minh Luu; Daniel Kütting; Christian Jansen; Julian Luetkens; Leon Marcel Bischoff; Ulrike Attenberger; Christian P Strassburg; Jonel Trebicka; Karsten Wolter; Michael Praktiknjo Journal: Sci Rep Date: 2022-03-03 Impact factor: 4.379